TCGA-85-7950-01A-11R-2187-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 46
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.530
- E2F_TARGETS+0.420
- G2M_CHECKPOINT+0.420
- INTERFERON_GAMMA_RESPONSE+0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- MYC_TARGETS_V2+0.300
- ALLOGRAFT_REJECTION+0.270
- TNFA_SIGNALING_VIA_NFKB+0.270
- MITOTIC_SPINDLE+0.260
- UNFOLDED_PROTEIN_RESPONSE+0.260
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- CHOLESTEROL_HOMEOSTASIS-0.330
- FATTY_ACID_METABOLISM-0.330
- XENOBIOTIC_METABOLISM-0.320
- ADIPOGENESIS-0.310
- OXIDATIVE_PHOSPHORYLATION-0.300
- COAGULATION-0.290
- HEME_METABOLISM-0.230
- PEROXISOME-0.230
- ESTROGEN_RESPONSE_EARLY-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-03093 | — | cohortA1 | 0.859 |
| 2 | TCGA-22-5480-01A-01R-1635-07 | — | cohortSQ1 | 0.845 |
| 3 | TCGA-85-A511-01A-21R-A262-07 | — | cohortSQ1 | 0.843 |
| 4 | TCGA-77-A5GH-01A-11R-A27Q-07 | — | cohortSQ1 | 0.833 |
| 5 | SRR934755 | — | — | 0.823 |
| 6 | SRR650184 | — | — | 0.816 |
| 7 | SRR650185 | — | — | 0.816 |
| 8 | C3L-04071 | — | cohortSQ1 | 0.809 |
| 9 | TCGA-BA-6873-01A-11R-1873-07 | — | — | 0.806 |
| 10 | a45a7511-4aa9-4d04-8f5f-34d12e4d5917 | — | — | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.180 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |